Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

A legfontosabb adatok

Ki végzi
VA Office of Research and Development
Hol
Portland (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
400 000 fő, tervezett
Kezdés
2022. szept. 26.
Várható befejezés
2027. szept. 30.
A vizsgálat típusa
Megfigyeléses, 4 csoport
A regiszteradat frissítve
2026. november 2.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 5 feltétel megnézéseKevesebb

Ki vehet részt

  • Phase 1:
  • Veterans with a laboratory-confirmed positive test for SARS-CoV-2 or a diagnosis of COVID-19 documented at any time since the beginning of the pandemic in January 2020 to present; Phase 2:
  • All Veterans alive and in Veterans Health Administration (VHA) care as of January 2018
  • Specific exclusion/inclusion criteria and observation periods will be further defined for each sub-study (See outcomes/publications)

Ki nem vehet részt

  • VA employees who are not enrollees

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • VA Portland Health Care System, Portland, ORPortland, Egyesült ÁllamokContact: Kristina L Bajema, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious diseases. This first phase will critically inform feasibility and direction of the second phase, in which the investigators will use target trial emulation design to study the comparative effectiveness of therapies and vaccines for COVID-19, respiratory viruses, including RSV, and influenza, and other infectious diseases.

A vizsgálat 4 csoportja

  • Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Feb 2022

    This cohort study assessed outpatient Veterans with risk factors for severe COVID-19 who tested positive for SARS-CoV-2 during January and February 2022. The purpose is to describe factors associated with receipt of outpatient COVID-19 pharmacotherapies in the Veterans Affairs (VA) health care system.

  • Nonhospitalized Veterans in VHA at risk for SARS-CoV-2 Jan-Jul 2022

    Three retrospective target trial emulation studies comparing matched cohorts of nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir- ritonavir versus molnupiravir. The purpose is to measure the effectiveness of nirmatrelvir-ritonavir and molnupiravir for outpatient treatment of COVID-19.

  • Outpatient Veterans who tested positive for SARS-CoV-2 from Jan 2022 through Jan 2023

    This cohort study evaluated nonhospitalized Veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases. The purpose is to analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA).

  • Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Jul 2022

    Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment. The purpose is to measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing Post COVID conditions.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
CSP #2038 - COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System (COPE-VA)
A regiszteradat frissítve
2026. november 2.